期刊文献+

galectin-3、HBME-1、CK19及RET在甲状腺肿瘤中的表达情况及其临床价值 被引量:5

Expressions of Galectin-3,HBME-1,CK19,and RET in Benign and Malignant Thyroid Tumor and Their Clinical Significances
原文传递
导出
摘要 目的分析半乳糖凝集素-3(galectin-3)、人骨髓内皮细胞-1(HBME-1)、细胞角蛋白(CK)19及RET在甲状腺良、恶性肿瘤中的表达情况,探讨其在诊断甲状腺肿瘤中的临床价值。方法收集2009~2012年期间我院甲状腺外科经手术切除的131例甲状腺肿瘤患者的临床病理资料,其中甲状腺恶性肿瘤患者45例,甲状腺良性肿瘤患者86例,应用免疫组织化学方法检测galectin-3、HBME-1、CK19及RET在甲状腺良、恶性肿瘤中的表达情况。结果 galectin-3、HBME-1、CK19及RET在45例甲状腺恶性肿瘤患者中的表达阳性率分别为97.8%(44/45)、88.9%(40/45)、100%(45/45)及71.1%(32/45),均明显高于其在86例甲状腺良性疾病患者中的表达阳性率〔分别为9.3%(8/86)、12.8%(11/86)、37.2%(32/86)及8.1%(7/86)〕,差异均有统计学意义(P<0.05)。galectin-3、HBME-1、CK19及RET诊断甲状腺良、恶性疾病的灵敏度分别为97.8%、88.9%、100%及71.1%,特异度分别为90.7%、87.2%、62.8%及91.9%,诊断符合率分别为93.1%、87.8%、75.6%及84.7%。结论 galectin-3、HBME-1、CK19及RET均在甲状腺恶性肿瘤中表达增强,是甲状腺良、恶性疾病病理诊断中有价值的辅助诊断指标,其中galectin-3对甲状腺恶性肿瘤的诊断有较高的参考价值,联合检测可以较大程度上提高甲状腺癌的诊断率。 Objective To analyze the expressions ofgalectin-3, human bone marrow endothelial cell-1 (HBME-1), cytokeratin (CK) 19, and RET in benign and malignant thyroid tumor and to discuss their clinical significances. Methods The clinicopathologic and immunohistochemical staining data of 131 patients with benign and malignant thyroid tumor were analyzed retrospectively, including 45 patients with malignant thyroid tumor, 86 patients with benign thyroid tumor. The expressions of galectin-3, HBME-1, CK19, and RET in the benign and malignant thyroid tumor were detected by immunohistochemical staining. Results The positive expression rates of the galectin-3, HBME-1, CK19, and RET in the malignant thyroid tumor were 97. 8% (44/45), 88. 9% (40/45), 100% (45/45), and 71.1% (32/45), respectively, which in the benign thyroid tumor were 9. 3% (8/86), 12. 8% (11/86), 37.2% (32/86), and 8. 1% (7/86), respectively, the differences were statistically significant (P〈0.05). The diagnostic sensitivity, specificity, and accordance rates were 97. 8 %, 90. 7%, and 93.1% for the galectin-3, respectively; 88.9%, 87. 2%, and 87.8% for the HBME-1, respec- tively; 100%, 62. 8%, and 75.6% for the CK19, respectively; 71.1%, 91.9%, and 84. 7% for the RET, respectively. Conclusions The expression levels of galectin-3, HBME-1, CK19, and RET in malignant thyroid tumor are significantly higher than those in benign thyroid tumor. Galectin-3, HBME-1, CK19, and RET can be important factors for identifying the benign and malignant tumor and their biological behaviors. Galectin-3 has a high reference value in the diagnosis of thyroid carcinoma.
出处 《中国普外基础与临床杂志》 CAS 2013年第2期156-160,共5页 Chinese Journal of Bases and Clinics In General Surgery
关键词 甲状腺肿瘤 半乳糖凝集素-3 人骨髓内皮细胞-1 细胞角蛋白19 RET 免疫组织化学 Thyroid tumor Galectin-3 Human bone marrow endothelial cell-l Cytokemtin 19 PET Immu-nohistochemistry
  • 相关文献

参考文献25

  • 1吴在德,吴肇汉.外科学[M].北京:人民卫生出版社,2005:475.
  • 2Hundahl SA, Fleming ID, Frengen AM, et al. A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the U. S, 1985-1995 [J]. Cancer, 1998, 8302): 2638-2648.
  • 3Chen AY, Jemal A, Ward EM. Increasing incidence of differenti- ated thyroid cancer in the United States, 1988-2005 [J]. Cancer, 2009, 115(16): 3801-3807.
  • 4Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma [J]. Mod Fathol, 2001, 14(4): 338-342.
  • 5Liberman E, Weidner N. thyroid gland. Differential Papillary and follicular neoplasms of the staining with high- Appl Immunohisto- molecular-weight keratin and involucrin [J] chem Mol Morphol, 2000, 8(1): 42-48.
  • 6Saleh HA, Jin B, BarnweU J, et al. Utility ofimmunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules [J]. Diagn Pathol, 2010, 5: 9.
  • 7Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kipl) in the differential diagnosis of thyroid nodules [J]. J Korean Med Sci, 2007, 22(4): 621-628.
  • 8Beesley MF, Mclaren KM. Cytokeratin 19 and galectin-3 immuno- histochemistry in the differential diagnosis of solitary thyroid nodules [ J ]. Histopathology, 2002, 41 (3): 236-243.
  • 9Volante M, Bozzalla-Cassione F, Orlandi F, et al. Diagnostic role of galectin-3 in follicular thyroid tumors [J]. Virchows Arch, 2004, 444(4): 309-312.
  • 10de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the.diagnosis of thyroid malignancy [J]. Histopathology, 2005, 47 (4): 391-401.

二级参考文献23

共引文献231

同被引文献26

  • 1Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients[J]. Ann Surg Oncol, 2012, 19(6): 1874-1880.
  • 2Papale F, Cafiero G, Grimaldi A, et al, Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation[J]. J Cell Physiol, 2013, 228(5): 968-974.
  • 3Nga ME, Lim GS, Soh CH, et al. HBME-I and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma[J]. Diagn Cytopathol, 2008, 36(8): 550-556.
  • 4Ord6fiez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis : a review and update[J]. Appl Immunohistochem Mol Morphol, 2012, 20(5): 429-444.
  • 5Tan A, Etit D, Bayol U, et al. Comparison of proliferating cellnuclear antigen, thyroid transcription factor-l, Ki-67, 063, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma[J]. Ann Diagn Pathol, 2011, 15(2): 108- 116.
  • 6Seqkin S, Karagece U. Expression of CK-19, cErbB2, galectin-3, and p53 in papillary thyroid carcinomas[J]. Turk J Med Sci, 2010, 40(2): 207-212.
  • 7刘剑鸣,王志明,李新营.甲状腺癌分子生物学的研究进展[J].中国普通外科杂志,2010,19(5):564-568. 被引量:12
  • 8徐冬香,游庆华,王爱华,叶惠英.Survivin和Smac在甲状腺肿瘤中的表达及意义[J].中国医药导报,2011,8(16):109-111. 被引量:5
  • 9孙红芹,赵长林,胡芳娟,张甘露,张超,杨扬.直肠癌组织Smac与Survivin表达及其临床意义的探讨[J].中华肿瘤防治杂志,2011,18(12):956-960. 被引量:7
  • 10郑荣寿,张思维,吴良有,李光琳,赵平,赫捷,陈万青.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤,2012,21(1):1-12. 被引量:564

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部